SLNB or ALND for staging of EBC in Australia?

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.651, 2012-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BP programmes to prevent stroke worthwhile in Australia?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 649, 2012-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?

By Chim Lesley Kelly Patrick J. Salkeld Glenn Stockler Martin R.

PharmacoEconomics, Vol. 28, Iss. 6, 2010-06 ,pp. : 463-475

Adis International

Access to resources Recommend Favorite

CYP2D6 genetic testing cost effective in EBC in Canada?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Should Australia introduce lamivudine for chronic hep B?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 270, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Cure for dysentery?

Inpharma, Vol. 1, Iss. 1232, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite